Navigation Links
Premier Biomedical Successfully Advances Cancer Research
Date:12/5/2012

ST. PETERSBURG, Fla., Dec. 5, 2012 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced successful advances in its cancer-focused research.  Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer's development.  This was accomplished utilizing the Felder Doctrine™: "Physically remove the pathophysiologic basis of the disease." 

Dr. Mitchell S. Felder, Chairman of Premier Biomedical, Inc.'s Scientific Advisory Board, stated: "At best, conventional methods, such as chemotherapy and many current marketed cancer-fighting drugs, can target only one single antigen, thus allowing another antigen to survive the treatment and enabling the cancer to progress.  Plus, these blockers or inhibitors often come with dangerous side effects to the patient.  Premier Biomedical aims for far greater efficacy through mixing and matching multiple cancer target antigens simultaneously.  We actually remove the pathophysiologic basis of the disease – targeting the exact cause of the disease and eliminating it – without dangerous side effects."

Specifically, the researchers removed a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy.  This may open the door to a methodology for eradicating cancer tissue without the use of any other medications and/or procedures that are often accompanied by related side effects.  Further testing has resulted in the successful removal of additional critical cancer-related antigens which are important in the development, growth, and metastasis of cancer tissue.  Leukemia and lymphoma cancers were the focus of these recent successes.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer.  Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis.  Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania.  The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."  www.premierbiomedicalinc.com

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management.  Actual results could differ materially from current projections or implied results.  Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact

Premier Biomedical, Inc.
William A. Hartman, CEO
(814) 786-8849
info@premierbiomedicalinc.com


'/>"/>
SOURCE Premier Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ekahau - A Preferred Provider of Real-Time Location Solutions - Is Awarded an Agreement with the Premier Healthcare Alliance
2. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
3. Premier Wen Visits Asymchems Tianjin Facility
4. Speech and Language Therapy Jobs and Biomedical Science Jobs - Medicspro Leading the way for Medical Recruitment Agencies in the UK
5. Arecor Awarded Biomedical Catalyst Funding Towards £1.3 Million Project
6. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
7. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
8. Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs
9. QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments
10. Bunker Hill Community College Holds Biomedical Careers Graduation Ceremony
11. Fluke Biomedical training center goes global: adds multi-language support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):